News | Ultrasound Women's Health | November 19, 2018

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

Completes first joint installation of AI-based system for concurrent reading with Invenia ABUS from GE Healthcare

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018

November 19, 2018 – QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (AI) computer-aided detection (CAD) system for concurrent reading of automated breast ultrasound (ABUS) exams, at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25-30, in Chicago. Being demonstrated for the first time since being approved, QVCAD reduces interpretation time of screening ABUS exams while maintaining diagnostic accuracy.  

In addition, QView successfully completed an installation of QVCAD at Northern Arizona Healthcare, the first joint installation with the Invenia ABUS system from GE Healthcare. Invenia ABUS is approved by the FDA for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breasts. “We are excited to add the capability to offer ABUS as part of our comprehensive breast cancer screening program, which will help improve cancer detection for women with dense breasts. However, it was important that we implement with concurrent decision support from QVCAD to improve reading times while maintaining workflow and diagnostic confidence,” said Liz Palomino, MHA, RT, Northern Arizona Healthcare director of medical imaging, Flagstaff Medical Center, Sedona Medical Center, Verde Valley Medical Center and Verde Valley Medical Imaging Center.

Results from several clinical studies have shown that the addition of ABUS to screening mammography results in a significant increase in cancer detection in women with dense breasts. However, the interpretation of ABUS exams, with up to 2,000 images per case, is complex and time consuming, particularly for new users. According to results of a reader study published recently in the American Journal of Radiology, QVCAD reduced reader interpretation time by 33 percent while maintaining diagnostic accuracy.

Based on deep learning algorithms, the AI system is designed to detect suspicious areas of breast tissue with characteristics similar to breast lesions, and highlight suspicious area to distinguish potentially malignant lesions from normal breast tissue.  QVCAD is FDA-approved for use with ABUS systems and has received the CE mark for use with ABUS/ABVS systems.

To improve reader productivity, QVCAD provides synthetic 2-D images of all six volumetric datasets in a standard ABUS exam to provide an immediately visual overview of the case. The C-thru images, which are minimum intensity projections (MinIP), summarize each 3-D ABUS volume in a 2-D image. They bring attention to specific areas of interest by enhancement of radial spiculations and retraction patterns in coronal reconstructions, which are highly suggestive of breast cancer in ABUS. Users may select any CAD mark or area of interest on the C-thru image and the corresponding original ABUS images will be displayed, enabling users to efficiently review the entire ABUS case.

For more information: www.qviewmedical.com

Related Content

Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...
News | Cybersecurity | August 20, 2019
Healthcare data breaches are currently being reported at a rate of more than one a day, according to a new report from...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

Sponsored Content | Case Study | Radiation Dose Management | August 13, 2019
Radiation dose management is central to child patient safety. Medical imaging plays an increasing role in the accurate...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...